![Amino acid sequence of variable heavy and light domains of RhumAb VEGF... | Download Scientific Diagram Amino acid sequence of variable heavy and light domains of RhumAb VEGF... | Download Scientific Diagram](https://www.researchgate.net/profile/Girolamo-Ranieri-2/publication/6943909/figure/fig3/AS:394406600429591@1471045269804/Fig-3-Amino-acid-sequence-of-variable-heavy-and-light-domains-of-RhumAb-VEGF-A461_Q320.jpg)
Amino acid sequence of variable heavy and light domains of RhumAb VEGF... | Download Scientific Diagram
![Structure of Bevacizumab. The humanised Bevacizumab antibody consists... | Download Scientific Diagram Structure of Bevacizumab. The humanised Bevacizumab antibody consists... | Download Scientific Diagram](https://www.researchgate.net/publication/288534026/figure/fig4/AS:556657223454720@1509728832546/Structure-of-Bevacizumab-The-humanised-Bevacizumab-antibody-consists-of-six-murine.png)
Structure of Bevacizumab. The humanised Bevacizumab antibody consists... | Download Scientific Diagram
![Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab | Eye Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab | Eye](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Feye.2011.66/MediaObjects/41433_2011_Article_BFeye201166_Fig1_HTML.jpg)
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab | Eye
![The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor](https://www.thno.org/v10/p1107/toc.jpg)
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
![WO2017181021A1 - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents WO2017181021A1 - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents](https://patentimages.storage.googleapis.com/f9/06/e2/d4b2c00a351866/imgf000065_0001.png)
WO2017181021A1 - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents
Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
![Frontiers | Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma Frontiers | Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma](https://www.frontiersin.org/files/Articles/515556/fimmu-11-515556-HTML/image_m/fimmu-11-515556-g001.jpg)
Frontiers | Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
![Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice | SpringerLink Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-020-00705-1/MediaObjects/11523_2020_705_Fig3_HTML.png)
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice | SpringerLink
![Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology | Future Oncology Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.14.276/asset/images/medium/figure3.gif)
Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology | Future Oncology
![Primary sequence representation of HX-MS labeling. Peptide level HX... | Download Scientific Diagram Primary sequence representation of HX-MS labeling. Peptide level HX... | Download Scientific Diagram](https://www.researchgate.net/publication/51536461/figure/fig3/AS:277056895111175@1443066920019/Primary-sequence-representation-of-HX-MS-labeling-Peptide-level-HX-labeling-patterns-of.png)
Primary sequence representation of HX-MS labeling. Peptide level HX... | Download Scientific Diagram
![FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-020-01140-9/MediaObjects/41416_2020_1140_Fig2_HTML.png)
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
![IMGt Protein displays of the VH and V-KAPPA domains of the bevacizumab... | Download Scientific Diagram IMGt Protein displays of the VH and V-KAPPA domains of the bevacizumab... | Download Scientific Diagram](https://www.researchgate.net/publication/50227918/figure/fig3/AS:650801320042509@1532174534969/IMGt-Protein-displays-of-the-VH-and-V-KAPPA-domains-of-the-bevacizumab-and-ranibizumab.png)
IMGt Protein displays of the VH and V-KAPPA domains of the bevacizumab... | Download Scientific Diagram
![In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S - Adv Biomed Res In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S - Adv Biomed Res](https://www.advbiores.net/articles/2012/1/1/images/AdvBiomedRes_2012_1_1_21_98122_f1.jpg)
In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S - Adv Biomed Res
![The multiple sequence alignment of known commercial antibodies s used... | Download Scientific Diagram The multiple sequence alignment of known commercial antibodies s used... | Download Scientific Diagram](https://www.researchgate.net/publication/323699991/figure/fig1/AS:614048131477519@1523411891768/The-multiple-sequence-alignment-of-known-commercial-antibodies-s-used-for-determining.png)
The multiple sequence alignment of known commercial antibodies s used... | Download Scientific Diagram
![Molecules | Free Full-Text | Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma Molecules | Free Full-Text | Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma](https://www.mdpi.com/molecules/molecules-24-03046/article_deploy/html/images/molecules-24-03046-g001-550.jpg)
Molecules | Free Full-Text | Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
![Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer | Cell Death & Disease Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer | Cell Death & Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41419-020-03111-7/MediaObjects/41419_2020_3111_Fig1_HTML.png)